Antonio Anzueto, MD
Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Scott Cerreta, BS, RRT
Tuba City Regional Health Care Corporation
Tuba City, Arizona
Chronic obstructive pulmonary disease (COPD) is an irreversible lung disease that plagues patients with chronic cough, phlegm production, potentially life-threatening exacerbations, and deteriorating lung function over the latter years of their life. One of the central goals in COPD management is the prevention of exacerbations, due not only to the acute risk of the event itself, but also an associated increase in the longer-term risk for future exacerbations. Current guidelines on the management of COPD provide comprehensive recommendations for both the treatment of exacerbations and the management of stable disease. However, the frequent rate of COPD-related hospitalization and poor prognosis for individuals following treatment for an acute exacerbation suggests that patient needs are not being adequately met by current practices in hospital and community settings.
Clinicians should be well-versed in current guidelines for the treatment of COPD, as well as the full spectrum of medications and delivery devices that are available in order to provide disease management that is appropriately tailored to the physical and cognitive needs of their patients with COPD. This knowledge and skill will enable them to provide care that can effectively reduce symptom severity and the risk of future exacerbations, increase physical activity, and improve overall quality of life in patients with COPD. This program will improve the knowledge and competence of clinicians who care for patients with COPD in order to achieve these objectives.
This educational initiative has been designed for respiratory therapists, internal medicine physicians, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with COPD.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME/CRCE credit for this activity. During the period of February 21, 2019 through February 21, 2020, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
This program has been approved for a maximum of 1.25 contact hours Continuing Respiratory Care Education (CRCE) credit by the AARC, 9425 N. MacArthur Blvd., Suite 100, Irving, TX 75063. Course #180844000
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Antonio Anzueto, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Sunovion Pharmaceuticals, Inc.
Scott Cerreta, BS, RRT
Has no conflicts of interest to disclose.
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.